GlassScriptPhysician profile
Ephrem H Paradela
NPI 1942227996
$6,136.62
in general payments reported to CMS, 2019-2025
30 companies · $925 in 2025
The $925 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,227 · 2020: $1,232 · 2021: $717 · 2022: $484 · 2023: $865 · 2024: $685 · 2025: $925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,476.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,044.18 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $744.89 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $558.36 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $479.65 | 2019-2025 | Jardiance |
| Daiichi Sankyo INC. | $437.18 | 2019-2022 | |
| Amgen INC. | $396.80 | 2021-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $362.94 | 2020-2025 | |
| Abbott Laboratories | $325.24 | 2022-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $294.36 | 2019-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $253.89 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $221.74 | 2019-2020 | |
| Amarin Pharma, INC. | $207.50 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $191.54 | 2019-2023 | Steglatro, Verquvo, Steglujan |
| Glaxosmithkline, LLC. | $122.92 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $121.04 | 2019-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $63.21 | 2025 | Cologuard Collection Kit |
| Optinose US, INC. | $46.82 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $38.27 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $36.74 | 2019 | |
| Novartis Pharmaceuticals Corporation | $25.57 | 2019 | |
| Dexcom, INC. | $23.65 | 2023 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $22.84 | 2024 | |
| Astellas Pharma US INC | $17.04 | 2023 | Veozah |
| Averitas Pharma INC. | $15.81 | 2024 | Qutenza |
| Sanofi Pasteur INC. | $14.89 | 2019 | |
| Ibsa Pharma INC. | $14.59 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $14.22 | 2020 | |
| Arbor Pharmaceuticals, INC. | $14.17 | 2021 | |
| Philips North America LLC | $13.32 | 2020 | |
| Hologic Sales and Service, LLC | $13.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ephrem Paradela listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.